Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib + Sotorasib ± Defactinib in KRAS G12C NSCLC
NCT05074810Phase 2Active, not recruiting
- Sponsor
- Verastem Oncology
- Start
- Apr 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of avutometinib in non-small cell lung cancer (NSCLC), sponsored by Verastem Oncology. Started Apr 2022; status: active, not recruiting.
02
Drugs
avutometinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05074810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074810.